QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 legendary-investor-stanley-druckenmiller-made-huge-ai-and-chipmaker-bets-in-q2--heres-what-he-knows-that-you-dont

See Stanley Druckenmiller's Q2 13F filing. Duquesne adds Microsoft and big banks, cuts Coupang, and makes a bullish bet on ...

 springworks-therapeutics-receives-ec-conditional-marketing-approval-for-ezmekly-in-treating-nf1-pn-across-pediatric-and-adult-patients

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commi...

 springworks-therapeutics-secures-ema-chmp-endorsement-for-conditional-approval-of-mirdametinib-in-nf1-pn-treatment

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for...

 guggenheim-reiterates-neutral-on-springworks-therapeutics-maintains-47-price-target

Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Neutral and maintains $47 price ...

 hc-wainwright--co-downgrades-springworks-therapeutics-to-neutral-lowers-price-target-to-47

HC Wainwright & Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lower...

 correction-guggenheim-downgrades-springworks-therapeutics-to-neutral-lowers-price-target-to-47-firm-change-from-stephens--co-to-guggenheim

Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lowers...

 td-cowen-downgrades-springworks-therapeutics-to-hold-lowers-price-target-to-47

TD Cowen analyst Yaron Werber downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Hold and lowers the price target...

 barclays-downgrades-springworks-therapeutics-to-equal-weight-lowers-price-target-to-47

Barclays analyst Peter Lawson downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Overweight to Equal-Weight and lowers t...

 merck-germany-buys-us-cancer-drugmaker-springworks-therapeutics-for-around-4-billion

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

Core News & Articles

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3....

 germanys-merck-nears-roughly-35-billion-deal-for-springworks-merck-and-springworks-have-agreed-on-a-price-close-to-47-per-share---wsj

https://www.wsj.com/business/deals/germanys-merck-nears-roughly-3-5-billion-deal-for-springworks-2c7258b9

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION